|1.||Luszczki, Jarogniew J: 18 articles (02/2016 - 04/2003)|
|2.||Czuczwar, Stanislaw J: 14 articles (11/2013 - 04/2003)|
|3.||Czuczwar, Stanisław J: 9 articles (01/2011 - 07/2004)|
|4.||D'Souza, Joseph: 9 articles (11/2006 - 05/2002)|
|5.||Patsalos, Philip N: 8 articles (12/2013 - 02/2002)|
|6.||Cansu, Ali: 7 articles (01/2015 - 11/2006)|
|7.||Marson, Anthony G: 6 articles (01/2013 - 01/2007)|
|8.||Stepanović-Petrović, Radica M: 6 articles (01/2011 - 10/2004)|
|9.||Tomić, Maja A: 6 articles (01/2011 - 10/2004)|
|10.||Prostran, Milica S: 6 articles (04/2010 - 10/2004)|
08/01/2001 - "According to the efficacy and safety profile established in the controlled trials, oxcarbazepine represents an important new treatment option indicated for monotherapy and adjunctive therapy in adults with partial seizures and as adjunctive therapy in children aged 4 years or older with partial seizures. "
09/01/2006 - "Overall, 70% experienced a significant reduction in seizures, and 50% became seizure-free while receiving oxcarbazepine. "
01/01/2001 - "Additionally, adjunctive therapy with oxcarbazepine was significantly more effective than placebo at reducing seizure frequency in children and adolescents with refractory partial seizures. "
11/01/2007 - "Seizures improved within 4 days of oxcarbazepine initiation in six children, whereas two children required higher doses. "
01/01/2009 - "The oxcarbazepine doses of 1,200 mg (RR 17.59; 95% CI 2.37 to 130.35) and 2,400 mg (RR 25.41; 95% CI 6.26 to 103.10) were effective for keeping patients probably free from seizures, but the dose of 600 mg was not. "
05/01/2003 - "Oxcarbazepine is a second-generation antiepileptic drug (AED) with proven efficacy in managing partial epileptic seizures, with or without secondary generalization, in adults and children. "
10/01/2013 - "Oral loading of oxcarbazepine suspension followed by maintenance dosing is well tolerated and effective in steadily achieving the therapeutic level of MHD in selected patients with epilepsy."
09/01/2003 - "Oxcarbazepine is a recently introduced AED that is effective in treating epilepsy and has an improved side-effect profile compared to existing therapies. "
11/01/1997 - "Oxcarbazepine appears to be an effective and well-tolerated drug for localization-related early childhood epilepsy. "
08/01/2014 - "This study was to establish the population pharmacokinetic (PPK) model of pharmacologically active metabolite of oxcarbazepine (OXC) and to estimate PPK parameters for the optimal individuation administration of OXC in Chinese children with epilepsy. "
|3.||Partial Epilepsies (Epilepsy, Partial)
05/01/2007 - "This study prospectively examined whether continued add-on treatment with oxcarbazepine (OXC) is associated with quantitative improvement in mood and anxiety symptoms in adult patients with partial epilepsy. "
01/01/2003 - "As a result, we found oxcarbazepine safe and effective in children with either generalized or partial epilepsy."
07/01/2015 - "The objective of this study was to explore the efficacy of low dose of oxcarbazepine (OXC) in adult patients with newly diagnosed partial epilepsy in an actual clinical setting. "
07/01/2015 - "Efficacy of low to moderate doses of oxcarbazepine in adult patients with newly diagnosed partial epilepsy."
05/01/2013 - "[Clinical efficacy of oxcarbazepine suspension in children with focal epilepsy]."
|4.||Bipolar Disorder (Mania)
08/01/2003 - "Oxcarbazepine appeared effective in about one half of patients with bipolar disorder and was well tolerated."
07/01/2006 - "To review the data on the efficacy of oxcarbazepine (OXC) in bipolar disorder (BD) and to provide recommendations for clinicians on the use of this medication in treating BD. "
01/01/2011 - " There is a need for adequately powered randomised controlled trials of good methodological quality to inform us of the therapeutic potential of oxcarbazepine across the spectrum of acute episodes in bipolar disorder."
01/01/2011 - "Currently, there are insufficient trials of adequate methodological quality on oxcarbazepine in the acute treatment of bipolar disorder to inform us on its efficacy and acceptability. "
01/01/2011 - " was no difference in the primary outcome analysis - a fall of 50% or more on the Young Mania Rating Scale (YMRS) - between oxcarbazepine and placebo (N=1, n=110, OR =2.10, 95% CI 0.94 to 4.73) in one study, conducted in children; no studies were available in adult participants.In"
10/01/2005 - "His pain responded dramatically to the addition of oxcarbazepine, with rapid improvement in his symptoms and functional status. "
11/01/2014 - "In the total sample, oxcarbazepine relieved pain of 0.7 points (on a numeric rating scale 0-10; 95% confidence interval [CI] 0.4-1.4) more than placebo (P=0.015) and there was a significant interaction between treatment and phenotype of 0.7 (95% CI 0.01-1.4, P=0.047). "
01/01/2013 - "We also searched the National Institutes of Health (NIH) databases and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials, and wrote to the companies who make oxcarbazepine and to pain experts asking for additional information. "
06/01/2006 - "The efficacy and safety of oxcarbazepine were evaluated according to the changes in pain intensity and social interference subitems scores of Short-form Brief Pain Inventory besides electrophysiological studies at the end of six months of the treatment. "
11/01/2007 - "The involvement of peripheral alpha 2-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain."
|5.||Valproic Acid (Valproate, Semisodium)
|9.||Anticonvulsants (Antiepileptic Drugs)
|1.||Vagus Nerve Stimulation
|3.||Psychology Biofeedback (Biofeedback)